Cellular Senescence and COVID-19 Long-Hauler Syndrome

N/AActive Not RecruitingNCT04903132

Mayo Clinic200 enrolled

Overview

The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, should be initiated.

Assays for cellular senescence markers, SASP factors, inflammatory mediators, pro-fibrotic factors, and auto-antibodies in blood and urine will be conducted in patients who provide informed consent. Data will be related to subject age, date of COVID-19 infection, severity of that infection, current Long-Hauler Syndrome symptoms), physical examination findings, underlying conditions, and laboratory data. To understand if an association between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than controls in this pilot study.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

SARS-CoV2 Infection

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Longhauler's Cohort - Inclusion Criteria: * Ability to give informed consent or LAR. * At least 18 years old. * Ability of subject or LAR to read and speak the English language. * Positive PCR or antibody test within 12 months of initial study visit. * Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome. Exclusion Criteria: * Any potential participant who refuses medical record review. * Pregnant females. * Incarcerated individuals. * Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study. Control Cohort - Inclusion Criteria: * Ability to give informed consent * At least 18 years old * Ability of subject to read and speak the English language Exclusion Criteria: * Known case of COVID-19. * Any potential participant who refuses medical record review. * Pregnant females. * Incarcerated individuals. * Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study. COVID-19 Control Cohort Inclusion Criteria: * Ability to give informed consent. * At least 18 years old. * Ability of subject to read and speak the English language. * Known case of COVID-19. Exclusion Criteria: * Known Longhauler's syndrome/Post-COVID * Any potential participant who refuses medical record review. * Pregnant females. * Incarcerated individuals. * Inability to cooperate or any medical condition that interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors

If a correlation between features of Long-Hauler Syndrome with markers of cellular senescence and SASP factors can be demonstrated, or SASP factors are higher in Long-Hauler Syndrome clinic patients than age- and sex-matched controls (using archived samples) in this pilot study, a protocol will be submitted to the IRB for a trial in Long-Hauler Syndrome patients of senolytic drugs.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.